A real-world study of recombinant human endostatin combined with PD-1/PD-L1 blockade and chemotherapy for patients with advanced non-small cell lung cancer negative for actionable molecular biomarkers

The ongoing ENPOWER study exploring the efficacy and safety of the recombinant human endostatin (endostar) combined with programmed cell death 1 antibody sintilimab and chemotherapy showed encouraging efficacy and safety in advanced non-squamous non-small cell lung cancer. To evaluate the real-world...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jing-Wen, Wang, Yin-Shuang, Gu, Hang-Yu, Meng, Zhuo-Nan, Wang, Fu-Wei, Wu, Guo-Qing, Zheng, Ai-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578728/
https://www.ncbi.nlm.nih.gov/pubmed/37832095
http://dx.doi.org/10.1097/MD.0000000000035243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578728/
https://www.ncbi.nlm.nih.gov/pubmed/37832095
http://dx.doi.org/10.1097/MD.0000000000035243

Ejemplares similares